Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.
The US market for PV devices is an evolving market, where a large undiagnosed patient population and innovative product launches will allow for significant expansion through 2027.
This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for PV devices in the US across a 10-year period.
Peripheral DCBs have experienced strong growth in the years following their commercial launch.
What effect will data highlighting safety concerns with paclitaxel-coated devices have on the DCB market?
To what degree will DCBs be adopted in the US over the forecast period?
How will recent reimbursement changes affect the adoption of DCBs over the forecast period?
How many competitors will enter the DCB market, and who will gain the most market share?
How will DCB uptake affect other PV devices such as stents, normal balloon catheters, and atherectomy devices?
What effect will the entry of a second SFA DES have on the DCB market?
Which new indications will drive growth in the DCB market?
A focus on noninvasive lower-extremity revascularization will contribute to increasing endovascular procedure volumes.
How will the adoption of and familiarity with CTO crossing devices affect the fem-pop and infrapop device markets?
How has CMS reimbursement affected the use of atherectomy by site of service?
What impact will the rising role of office-based procedures have on the lower-extremity market?
AV access procedures are increasingly being affected by changes to reimbursement.
How will the bundling of procedures affect reimbursement of these procedures in different sites of service?
Which site of service performs the largest volumes of AV access procedures?
Already a Client? Log in to access this report.
Fernando Amador is a principal analyst within the Cardiovascular Medtech Insights team at Decision Resources Group; he is DRG's authority on peripheral vascular and cardiac assist devices. Fernando holds a in Medical Biophysics from the Universtiy of Toronto, where he was a Banting and Best Scholar.